Before Ozempic, Wegovy, Mounjaro and Zepbound, there was Lotte Bjerre Knudsen.
In the 1990s, the young scientist at the Danish drug company Novo Nordisk was trying to unlock the key to a new technology for treating Type 2 diabetes. To her bosses, Lotte’s project, which focused on a hormone called GLP-1, looked like a distraction.
But as Lotte fought to save her diabetes project from the chopping block, she couldn’t have imagined how much of an impact her breakthrough would have. Her work would pave the way for a hit drug called Ozempic. And it would unleash a new class of blockbuster drugs, pitting two companies in a race to become the world’s first trillion-dollar pharmaceutical company by market cap.
Listen to Part 1 of “Trillion Dollar Shot” now.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Teens Are Falling Victim to AI Fake Nudes
The Resurrection of Abercrombie & Fitch
Gold Bars, Cash and a Mercedes: A U.S. Senator's Corruption Trial
Boeing Agrees to Felony Plea. Now Its Future Is Up in the Air.
Coinbase’s CEO on the Future of Crypto
McDonald’s Wants To Offer Quality And Value. Can It Do Both?
Will Biden Stay in the Race?
A Troubled Plan to Ship Migrants to Rwanda
Trump Has Broad Immunity
Farm-to-Table Pioneer on Why We Still Need Better Food
All Eyes on Biden, Trump – and CNN
How Ukraine Built a Weapon to Control the Black Sea
The Unusual Economics of the Bilt Credit Card
Southwest Changed Flying. Can It Change Itself?
Zyn pouches, ‘Zynfluencers’ and ‘the Zyndemic’
Sam Altman's Opaque Investment Empire
How ‘Conflict Gum’ Is Helping Fuel Sudan’s Civil War
The Brutal Calculation of Hamas’s Leader
Tesla’s Multibillion-Dollar Pay Package for Elon Musk
The Hidden Life of Google’s Secret Weapon
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Opinion: Potomac Watch
The Daily
Today, Explained